MK-1242
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $10.8M | 1,163 | 36 |
| 2018 | $10.6M | 1,907 | 67 |
| 2017 | $4.6M | 1,351 | 42 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.5M | 3,314 | 97.7% |
| Consulting Fee | $350,300 | 110 | 1.3% |
| Travel and Lodging | $232,949 | 453 | 0.9% |
| Food and Beverage | $22,910 | 544 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA | Merck Sharp & Dohme Corporation | $25.5M | 1 |
| A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA | Merck Sharp & Dohme Corporation | $230.40 | 0 |
Top Doctors Receiving Payments for MK-1242 — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Dallas, TX | $120.00 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Dallas, TX | $120.00 | 3 |
| , DO | Internal Medicine | Fort Collins, CO | $110.00 | 3 |
| , MD | Cardiovascular Disease | Durham, NC | $110.00 | 3 |
| , M.D | Cardiovascular Disease | Fort Collins, CO | $80.00 | 2 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $26.1M
- Total Doctors 104
- Transactions 4,421
About MK-1242
MK-1242 is a drug associated with $26.1M in payments to 104 healthcare providers, recorded across 4,421 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $10.8M was paid across 1,163 transactions to 36 doctors.
The most common payment nature for MK-1242 is "Unspecified" ($25.5M, 97.7% of total).
MK-1242 is associated with 2 research studies, including "A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA" ($25.5M).